{"nctId":"NCT02940886","briefTitle":"Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA)","startDateStruct":{"date":"2016-11-08","type":"ACTUAL"},"conditions":["Iron Deficiency Anaemia","Iron Deficiency Anemia"],"count":1512,"armGroups":[{"label":"Iron isomaltoside/ferric derisomaltose","type":"EXPERIMENTAL","interventionNames":["Drug: Iron isomaltoside/ferric derisomaltose"]},{"label":"Iron sucrose","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Iron sucrose"]}],"interventions":[{"name":"Iron isomaltoside/ferric derisomaltose","otherNames":["Monofer®, Monoferric®, Monover®, Monofar®, Monoferro®"]},{"name":"Iron sucrose","otherNames":["Venofer®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria includes:\n\n1. Men or women ≥ 18 years\n2. Subjects having IDA caused by different etiologies\n3. Subjects with intolerance to oral iron therapy or a need for rapid repletion of iron stores:\n4. Haemoglobin (Hb) ≤ 11 g/dL\n5. Transferrin Saturation (TSAT) \\< 20 %\n6. S-ferritin \\< 100 ng/mL\n7. Willingness to participate and signing the informed consent form\n\nExclusion Criteria includes :\n\n1. Anemia predominantly caused by factors other than IDA\n2. Hemochromatosis or other iron storage disorders\n3. Previous serious hypersensitivity reactions to any IV iron compound\n4. Erythropoiesis stimulating agent (ESA) treatment\n5. Prior to screening or during the trial period; has or will be treated with a red blood cell transfusion, radiotherapy, and/or chemotherapy\n6. Will require a surgical procedure that necessitated general anesthesia prior to screening or during the trial period\n7. Alanine aminotransferase and/or aspartate aminotransferase \\> 3 times upper limit of normal\n8. Required dialysis for treatment of chronic kidney disease (CKD)\n9. Alcohol or drug abuse within the past 6 months\n10. Pregnant or nursing women","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Hemoglobin (Hb) From Baseline to Week 8","description":"Efficacy\n\nEvaluate the effect on the hemoglobin (Hb) level following treatment with iron isomaltoside/ferric derisomaltose vs iron sucrose in subjects with iron deficiency anaemia (IDA) .\n\nResponse was defined as change from baseline in hemoglobin (Hb) to week 8, i.e. ability to increase Hb in subjects with IDA, when oral iron preparations were ineffective or could not be used or in whom the screening Hb measurement in Investigators' opinion were sufficiently low to require rapid repletion of iron stores.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.49","spread":null},{"groupId":"OG001","value":"2.49","spread":null}]}]}]},{"type":"PRIMARY","title":"Incidence of Protocol-defined Serious or Severe Hypersensitivity Reactions","description":"Safety\n\nFor this endpoint, the number of participants with serious or severe hypersensitivity reactions were evaluated. The hypersensitivity reactions that were included in the analysis were those that started on or after the first dose of randomised treatment (i.e. treatment emergent). The terms used to define hypersensitivity were those specified by the Standardised MedDRA Queries (SMQ) for hypersensitivity, plus four additional terms: loss of consciousness, seizure, syncope, unresponsiveness.\n\nThe potential hypersensitivity AEs were adjudicated in a blinded fashion by an independent Clinical Endpoint Adjudication Committee (CEAC).\n\nResults show only those participants that had adjudicated and confirmed serious or severe hypersensitivity reactions.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Composite Cardiovascular Adverse Events (AEs)","description":"Safety\n\nResults show the composite cardiovascular adverse events (AEs), that started on or after the first dose of randomised treatment (i.e. treatment emergent) up to week 8.\n\nThe reported potential cardiovascular AEs were adjudicated in a blinded fashion by an independent Clinical Endpoint Adjudication Committee (CEAC).\n\nThe potential cardiovascular AEs included the following:\n\n* Death due to any cause\n* Non-fatal myocardial infarction\n* Non-fatal stroke\n* Unstable angina requiring hospitalisation\n* Congestive heart failure requiring hospitalisation or medical intervention\n* Arrhythmias\n* Hypertension\n* Hypotension\n\nResults show only those participants that had adjudicated and confirmed treatment-emergent composite cardiovascular AEs.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to First Composite Cardiovascular Safety AE","description":"Safety\n\nTime to first composite cardiovascular AE was defined as the actual time in days from first dose of treatment until the date of the composite cardiovascular AE. For subjects not reporting a composite cardiovascular AE, the time was censored at the date of the last attended visit. Only the adjudicated and confirmed composite cardiovascular safety AEs, as judged by the CEAC, were considered for this endpoint.\n\nTime to first composite cardiovascular AE was defined as the actual time in days from first dose of treatment until the date of the composite cardiovascular AE. For subjects not reporting a composite cardiovascular AE, the time was censored at the date of the last attended visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"S-phosphate <2 mg/dL at Any Time From Baseline to Week 1, 2, 4, and 8","description":"Safety\n\nResults show the number of subjects who had s-phosphate \\<2 mg/dL at any time from baseline to week 1, 2, 4, or 8.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"Hb Concentration Increase of ≥2 g/dL From Baseline to Week 1, 2, 4, and 8","description":"Efficacy\n\nResults show responders to the treatment. A subject was considered a Hb responder to a certain week if an increase in Hb of at least 2 g/dL from baseline to the week in question was observed (week 1, 2, 4, and 8).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"297","spread":null},{"groupId":"OG001","value":"94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"514","spread":null},{"groupId":"OG001","value":"250","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"606","spread":null},{"groupId":"OG001","value":"309","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Change in Hb Concentration ≥2 g/dL","description":"Efficacy\n\nTime to change in Hb concentration ≥2 g/dL. Subjects who achieved Hb concentration increase of ≥2 g/dL (from baseline to week 1, 2, 4, or 8).\n\nFor responders, time to Hb response was defined as the scheduled time from baseline until the visit where the first Hb response was measured.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]}]},{"type":"SECONDARY","title":"Hb Concentration of >12 g/dL at Any Time From Week 1 to Week 8","description":"Efficacy\n\nHb concentration of \\>12 g/dL at any time from week 1 to week 8.\n\nResults show the number of participants who achieved Hb concentration of \\>12 g/dL at any time from week 1 to week 8.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"484","spread":null},{"groupId":"OG001","value":"225","spread":null}]}]}]},{"type":"SECONDARY","title":"Hb Concentration Increase of ≥2 g/dL at Any Time From Week 1 to Week 8","description":"Efficacy\n\nResults show the number of participants who achieved Hb concentration increase of ≥2 g/dL at any time from week 1 to week 8.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"687","spread":null},{"groupId":"OG001","value":"340","spread":null}]}]}]},{"type":"SECONDARY","title":"S-Ferritin Concentration of ≥100 ng/mL and Transferrin Saturation (TSAT) of 20-50% at Any Time From Week 1 to Week 8","description":"Efficacy\n\nProportion of subjects reaching the composite endpoint of s-ferritin concentration ≥100 ng/mL and TSAT of 20-50% at any time from week 1 to 8.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"680","spread":null},{"groupId":"OG001","value":"164","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Hb Concentration From Baseline to Week 1, 2, and 4","description":"Efficacy\n\nChange in Hb concentration from baseline to week 1, 2, and 4.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.70","spread":"0.85"},{"groupId":"OG001","value":"0.47","spread":"0.69"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.49","spread":"1.13"},{"groupId":"OG001","value":"1.25","spread":"0.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.15","spread":"1.27"},{"groupId":"OG001","value":"2.13","spread":"1.10"}]}]}]},{"type":"SECONDARY","title":"Change in S-ferritin Concentration From Baseline to Weeks 1, 2, 4, and 8","description":"Efficacy\n\nChange in s-ferritin concentration from baseline to weeks 1, 2, 4, and 8.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"373.5","spread":"228.9"},{"groupId":"OG001","value":"105.7","spread":"79.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"211.8","spread":"152.4"},{"groupId":"OG001","value":"169.9","spread":"129.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.0","spread":"103.9"},{"groupId":"OG001","value":"109.2","spread":"108.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.0","spread":"79.7"},{"groupId":"OG001","value":"58.7","spread":"104.8"}]}]}]},{"type":"SECONDARY","title":"Change in Transferrin Saturation (TSAT) From Baseline to Week 1, 2, 4, and 8","description":"Efficacy\n\nChanges in transferrin saturation (TSAT) from baseline to week 1, 2, 4, and 8.\n\nTSAT is the value of serum iron divided by the total iron-binding capacity and the unit is %, which referrers to % of iron-binding sites of transferrin being occupied by iron.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.68","spread":"15.66"},{"groupId":"OG001","value":"5.84","spread":"10.52"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.33","spread":"13.46"},{"groupId":"OG001","value":"10.58","spread":"12.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.63","spread":"12.09"},{"groupId":"OG001","value":"11.08","spread":"8.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.01","spread":"12.58"},{"groupId":"OG001","value":"8.87","spread":"9.03"}]}]}]},{"type":"SECONDARY","title":"Change in Concentrations of Serum Iron (S-iron) From Baseline to Week 1, 2, 4, and 8","description":"Efficacy\n\nChanges in the concentrations of serum iron (s-iron) from baseline to week 1, 2, 4, and 8.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.2","spread":"69.7"},{"groupId":"OG001","value":"22.4","spread":"44.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.8","spread":"58.1"},{"groupId":"OG001","value":"37.0","spread":"51.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.2","spread":"49.7"},{"groupId":"OG001","value":"35.1","spread":"33.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.2","spread":"53.3"},{"groupId":"OG001","value":"27.6","spread":"32.7"}]}]}]},{"type":"SECONDARY","title":"Change in Fatigue Symptoms From Baseline to Week 1, 2, and 8","description":"Efficacy\n\nChange in fatigue symptoms from baseline to week 1, 2, and 8 was measured by the Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale.\n\nThe Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale consisted of 13 items ranging from 0 (not at all) to 4 (very much), except items #7 and #8 which are reversed scored. The total score range is 0-52.\n\nA score of less than 30 indicated severe fatigue, and the higher the score, the better outcome/quality of life (QoL). If more than 50% of the items for a subject at a given visit were missing, the total score was not calculated.\n\nTotal score was calculated as shown below:\n\nTotal score= Sum of individual scores x 13 / Number of items answered","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.98","spread":"10.41"},{"groupId":"OG001","value":"7.38","spread":"9.38"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.74","spread":"11.58"},{"groupId":"OG001","value":"11.89","spread":"11.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.08","spread":"12.70"},{"groupId":"OG001","value":"15.36","spread":"12.87"}]}]}]},{"type":"SECONDARY","title":"Intervals in Screening for Diabetic Retinopathy (ISDR) Questionnaire, Cost of Public Transport/Taxi And Parking","description":"Pharmacoeconomics\n\nThe Intervals in Screening for Diabetic Retinopathy (ISDR) questionnaire at the baseline visit assessed the resources used by subjects to receive treatment. Resources used on other trial activities were not included. ISDR responses were summarised using descriptive statistics.\n\nThe data for this endpoint show the responses at baseline for both treatment groups.\n\nThe frequency of drug administration between the 2 treatment groups is different, however, (i.e. up to a factor 5 in the iron sucrose treatment group).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":null},{"groupId":"OG001","value":"5.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Intervals in Screening for Diabetic Retinopathy (ISDR) Questionnaire, Return Journey by Car","description":"Pharmacoeconomics\n\nThe Intervals in Screening for Diabetic Retinopathy (ISDR) questionnaire at the baseline visit assessed the resources used by subjects to receive treatment. Resources used on other trial activities were not included. ISDR responses were summarised using descriptive statistics.\n\nThe data for this endpoint show the responses at baseline for both treatment groups.\n\nThe frequency of drug administration between the 2 treatment groups is different, however, (i.e. up to a factor 5 in the iron sucrose treatment group).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.0","spread":null},{"groupId":"OG001","value":"15.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Intervals in Screening for Diabetic Retinopathy (ISDR) Questionnaire, Time Spent on Visit/Helping on Visit","description":"Pharmacoeconomics\n\nThe Intervals in Screening for Diabetic Retinopathy (ISDR) questionnaire at the baseline visit assessed the resources used by subjects to receive treatment. Resources used on other trial activities were not included. ISDR responses were summarised using descriptive statistics.\n\nThe data for this endpoint show the responses at baseline for both treatment groups.\n\nThe frequency of drug administration between the 2 treatment groups is different, however, (i.e. up to a factor 5 in the iron sucrose treatment group).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"2.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"2.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Intervals in Screening for Diabetic Retinopathy (ISDR) Questionnaire, Participants/Others Who Took Time Off Work to Attend Visits","description":"Pharmacoeconomics\n\nThe Intervals in Screening for Diabetic Retinopathy (ISDR) questionnaire at the baseline visit assessed the resources used by subjects to receive treatment. Resources used on other trial activities were not included. ISDR responses were summarised using descriptive statistics.\n\nThe data for this endpoint show the responses at baseline for both treatment groups.\n\nThe frequency of drug administration between the 2 treatment groups is different, however, (i.e. up to a factor 5 in the iron sucrose treatment group).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"529","spread":null},{"groupId":"OG001","value":"258","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"233","spread":null},{"groupId":"OG001","value":"113","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"211","spread":null},{"groupId":"OG001","value":"111","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]}]},{"type":"SECONDARY","title":"Health Care Resource Use Questionnaire","description":"Pharmacoeconomics\n\nResources used by the health care staff (per administration), measured by the health care resource use questionnaire. The questionnaire assessed the time used by the health care staff during administration of the investigational product and the administration time (including the observational time). The health care participants included in the evaluation were: investigator, pharmacist, physician, study coordinator, study nurse.\n\nThe data for this endpoint show the responses at baseline for both treatment groups.\n\nThe frequency of drug administration between the treatment groups is different (i.e. up to a factor 5 more frequent in the iron sucrose treatment group).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.08","spread":null},{"groupId":"OG001","value":"1.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.38","spread":null},{"groupId":"OG001","value":"3.00","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":21,"n":989},"commonTop":["Nausea"]}}}